- Ongoing, recruitingTherapeutic exploratory (Phase II)
DiaPrecise, A Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® in individuals at risk for Type 1 diabetes carrying the HLA DR3-DQ2 haplotype
This study looks at a new treatment called Diamyd for people at risk of type 1 diabetes. Researchers want to see if giving Diamyd injections into a lymph node is safe and possible. This is an early-stage study to gather important information.
For: Type 1 diabetes mellitusSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype
This study looks at a new treatment called Diamyd for teenagers and adults recently diagnosed with Type 1 diabetes. Researchers want to see if it can help preserve the body's natural ability to make insulin. It’s a major study to check how well it works and if it's safe.
For: Type 1 diabetes mellitusGermany · Spain · Czechia